MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.3 USD | -4.39% |
|
-6.15% | +17.96% |
| 05-10 | Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
| 05-10 | S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
ETFs positioned on Moderna, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.20% | 0 M€ | +4.20% | - | |
| 0.20% | 330 M€ | -.--% | ||
| 0.19% | 6 M€ | +17.98% | - | |
| 0.18% | 0 M€ | +6.97% | - | |
| 0.17% | 0 M€ | -.--% | - | |
| 0.17% | 0 M€ | +4.60% | - | |
| 0.17% | 0 M€ | +8.70% | ||
| 0.16% | 0 M€ | +18.44% | - | |
| 0.16% | 0 M€ | +8.67% | ||
| 0.15% | 0 M€ | +9.42% | ||
| 0.15% | 0 M€ | +12.13% | - | |
| 0.14% | 559 M€ | +14.30% | ||
| 0.14% | 1,848 M€ | +18.39% | ||
| 0.13% | 0 M€ | +8.15% | - | |
| 0.12% | 0 M€ | +19.88% | - | |
| 0.11% | 1,174 M€ | +23.54% | ||
| 0.11% | 273 M€ | -.--% | ||
| 0.11% | 655 M€ | -.--% | - | |
| 0.11% | 0 M€ | +9.18% | - | |
| 0.11% | 1 M€ | -.--% | ||
| 0.10% | 0 M€ | +18.92% | ||
| 0.09% | 0 M€ | +11.62% | - | |
| 0.09% | 0 M€ | +8.99% |
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B | |
| +20.18% | 11.72B |
- Stock Market
- Equities
- MRNA Stock
- Funds and ETFs Moderna, Inc.
